P
Paul A. Bunn
Researcher at University of Colorado Boulder
Publications - 547
Citations - 46298
Paul A. Bunn is an academic researcher from University of Colorado Boulder. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 106, co-authored 529 publications receiving 43253 citations. Previous affiliations of Paul A. Bunn include United States University & George Washington University.
Papers
More filters
Journal ArticleDOI
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma
Bernard J. Poiesz,Francis W. Ruscetti,Adi F. Gazdar,Paul A. Bunn,John D. Minna,Robert C. Gallo +5 more
TL;DR: The number of these particle-associated proteins is consistent with the expected proteins of a retrovirus, but the sizes of some are distinct from those of most known retroviruses of the primate subgroups.
Journal ArticleDOI
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Federico Cappuzzo,Fred R. Hirsch,Elisa Rossi,Stefania Bartolini,Giovanni Luca Ceresoli,Lynne T. Bemis,Jerry Haney,Samir E. Witta,Kathleen D. Danenberg,I. Domenichini,Vienna Ludovini,Elisabetta Magrini,Vanesa Gregorc,Claudio Doglioni,Angelo Sidoni,Maurizio Tonato,Wilbur A. Franklin,Lucio Crinò,Paul A. Bunn,Marileila Varella-Garcia +19 more
TL;DR: High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC and independent of EGFR assessment method, EGFR+/P-Akt+ patients had a statistically significantly better outcome than EGFR-, P- akt-, or EGFR-/Akt- patients.
Journal ArticleDOI
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
Fred R. Hirsch,Marileila Varella-Garcia,Paul A. Bunn,Michael V. Di Maria,Robert Veve,Roy M. Bremnes,Anna E. Barón,Chan Zeng,Wilbur A. Franklin +8 more
TL;DR: EGFR overexpression is frequent in NSCLC, is most prominent in SCC, and correlates with increased gene copy number per cell, and high gene copy numbers per cell showed a trend toward poor prognosis.
Journal ArticleDOI
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris,Bruce E. Johnson,Lynne D. Berry,David J. Kwiatkowski,A. John Iafrate,Ignacio I. Wistuba,Marileila Varella-Garcia,Wilbur A. Franklin,Samuel J. Aronson,Pei Fang Su,Yu Shyr,D. Ross Camidge,Lecia V. Sequist,Bonnie S. Glisson,Fadlo R. Khuri,Edward B. Garon,William Pao,Charles M. Rudin,Joan H. Schiller,Eric B. Haura,Mark A. Socinski,Keisuke Shirai,Heidi Chen,Giuseppe Giaccone,Giuseppe Giaccone,Marc Ladanyi,Kelly Kugler,John D. Minna,Paul A. Bunn +28 more
TL;DR: The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials.
Journal ArticleDOI
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
Karen Kelly,John Crowley,Paul A. Bunn,Cary A. Presant,Patra K. Grevstad,Carol M. Moinpour,Scott D. Ramsey,Antoinette J. Wozniak,Geoffrey R. Weiss,Dennis F. Moore,Valerie Israel,Robert B. Livingston,David R. Gandara +12 more
TL;DR: PC is equally efficacious as VC for the treatment of advanced non--small-cell lung cancer, and overall costs on the PC arm were higher than on the VC arm because of drug costs.